Ubs Group Ag Uro Gen Pharma Ltd. Transaction History
Ubs Group Ag
- $555 Billion
- Q2 2025
A detailed history of Ubs Group Ag transactions in Uro Gen Pharma Ltd. stock. As of the latest transaction made, Ubs Group Ag holds 308,527 shares of URGN stock, worth $5.92 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
308,527
Previous 1,173,088
73.7%
Holding current value
$5.92 Million
Previous $13 Million
67.43%
% of portfolio
0.0%
Previous 0.0%
Shares
32 transactions
Others Institutions Holding URGN
# of Institutions
148Shares Held
44MCall Options Held
146KPut Options Held
42.1K-
Rtw Investments, LP New York, NY4.54MShares$87.2 Million0.96% of portfolio
-
Toronto Dominion Bank Toronto, Ontario, A63.19MShares$61.3 Million0.08% of portfolio
-
Jefferies Financial Group Inc. New York, NY2.2MShares$42.2 Million0.27% of portfolio
-
Black Rock Inc. New York, NY2.19MShares$42.1 Million0.0% of portfolio
-
Vestal Point Capital, LP New York, NY2.15MShares$41.3 Million1.7% of portfolio
About UroGen Pharma Ltd.
- Ticker URGN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 22,740,500
- Market Cap $437M
- Description
- UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization novel solutions for specialty cancers and urothelial diseases. It offers RTGel, a polymeric biocompatible and reverse thermal gelation hydrogel to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead...